• Immunocore Holdings recently reported updated Phase 1/2 data for its ImmTAC molecule brenetafusp in heavily pretreated advanced melanoma, showing encouraging survival and disease control outcomes that informed selection of a 160 mcg dose for its ongoing Phase 3 PRISM-MEL-301 trial.
• The results presented at ASCO 2026 also suggested potential benefit in patients with primary PD-1 resistance and hinted at further upside from combinations, including with IL7, which could broaden the future role of ImmTAC therapies across difficult-to-treat tumors.
• Next, we’ll examine how these brenetafusp data in PD-1–resistant melanoma could reshape Immunocore’s investment narrative and pipeline expectations.

Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Immunocore Holdings Investment Narrative Recap

To own Immunocore, you need to believe its ImmTAC platform can turn KIMMTRAK’s uveal melanoma foothold into a broader oncology franchise, with brenetafusp in first line advanced melanoma a key test. The updated Phase 1/2 data strengthen the rationale for the Phase 3 PRISM-MEL trial and slightly improve visibility on that near term catalyst, but they do not remove the central risk that pivotal outcomes, timelines and eventual uptake may fall short of expectations.

Among recent announcements, the appointment of Anne Achola Sefu to the board matters most here, as fresh board oversight comes just as Immunocore leans further into late stage investment around brenetafusp and other ImmTAC assets. That added governance experience may influence how the company balances growing R&D spend, dependence on KIMMTRAK and decisions around future combinations or indications that could follow from the PRISM-MEL program.

Yet behind the encouraging melanoma data, investors should still be aware that prolonged R&D spending and any setback in PRISM-MEL could...

Immunocore Holdings' narrative projects $551.3 million revenue and $88.5 million earnings by 2028.

Uncover how Immunocore Holdings' forecasts yield a $66.57 fair value, a 133% upside to its current price.

Exploring Other Perspectives

Some analysts were already far more optimistic, assuming around US$655 million of revenue and positive earnings by 2028, so this new melanoma data could either reinforce or challenge that view.

Explore 3 other fair value estimates on Immunocore Holdings - why the stock might be worth just $63.49!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Immunocore Holdings research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Immunocore Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Immunocore Holdings' overall financial health at a glance.

Ready For A Different Approach?

Our top stock finds are flying under the radar-for now. Get in early:

• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Rare earth metals are the new gold rush. Find out which 27 stocks are leading the charge.
• Outshine the giants: these 14 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.